Cerluten

Cerluten is a synthetic tripeptide (Glutamic acid-Aspartic acid-Proline, Glu-Asp-Pro) belonging to Professor Khavinson's short peptide bioregulator family. It is formulated for the nervous system and shares the Glu-Asp dipeptide core with Crystagen (which has C-terminal Arg instead of Pro).

Like all Khavinson bioregulators, Cerluten is proposed to act as a gene-regulatory short peptide that can penetrate cell membranes and interact with DNA chromatin in a sequence-selective manner. The research framework, published primarily in Russian journals and translated works, suggests that these dipeptides and tripeptides derived from different organ tissues retain "informational" sequences that can upregulate transcription of specific genes in their target tissue.

Cerluten's proline residue vs Crystagen's arginine may alter its interaction profile with DNA promoter sequences. Proline-containing peptides have constrained conformational flexibility that may affect DNA-binding geometry and sequence selectivity in the chromatin-interaction model proposed by Khavinson.

In practice, Cerluten is used in Eastern European gerontological clinics and research protocols as part of multi-organ bioregulator stacks targeting nervous system aging, often combined with Epithalon (pineal), Thymalin (thymus), Cortagen (blood vessels), and Cartalax (cartilage) in comprehensive anti-aging protocols lasting 1-3 months.

Independent validation of the specific mechanisms claimed for Cerluten and its congeners remains limited in the Western peer-reviewed literature, though the broader peptide bioregulator field is an active area of inquiry. Computational studies of short peptide-DNA interactions provide mechanistic plausibility.